What Happened

OpenGraphs is raising funds to commercialize its AI-powered clinical trial statistical programming tool. The startup automates SAS/R code generation for regulatory submissions, currently a months-long manual process. Founder Weixing Chen (USC biostatistics) and CTO Xinrui Wang (U Tokyo AI) lead the team.

Who Is Affected

Top 20 pharma firms ($50B annual clinical ops spend) and CROs are primary targets. Statistical programmers face 95%+ repetitive coding tasks. Regulatory agencies will receive AI-generated but human-validated submissions.

Market Impact

• 1% AI adoption in clinical trials = $500M+ market
• Reduces average $2-5M trial cost by accelerating data lock
• Competes with legacy SAS services, not biostatisticians

What to Watch

Pilot partnerships with 2-3 pharma/CROs in 2024. Roadmap includes AI medical writing (2025) and safety tools (2026). SoftBank-affiliated AI advisor signals Japan market entry potential.